Beckman Coulter Diagnostics announced that the new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay analyzer, received 510(k) clearance from the U.S. FDA. The DxC 500i combines advanced technology with an intuitive user interface, ensuring that laboratories of all sizes can meet the growing demands of modern healthcare. With throughput of up to 800 clinical chemistry tests per hour and 100 immunoassay tests per hour, this analyzer delivers precise and reliable results critical for timely clinical decision-making.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher placed on ‘positive catalyst watch’ at Citi
- Unusually active option classes on open February 26th
- Early notable gainers among liquid option names on February 21st
- Danaher: Strategic Cost Savings Initiative and Resilient Management Underpin Buy Rating
- Danaher: Cost-Saving Initiatives and Growth Potential Amidst Stock Pressure
Questions or Comments about the article? Write to editor@tipranks.com